CASP4 and neoplasm: In contrast, NSCLC patients who had lower levels of caspase-4 (<0.377 ng/ml) in the tumor mass had longer median survival (3.02 years), which was three-fold higher compared to patients who had higher levels of caspase-4 (0.92 years).